Hydroxychloroquine for Prevention of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: Challenges to Trial Conduct During the Global Pandemic

Jason D Goldman^{1

2}

Affiliations

¹ Swedish Center for Research and Innovation, Swedish Medical Center, Seattle, Washington, USA.
² Division of Allergy and Infectious Disease, University of Washington, Seattle, Washington, USA.

Editorial

Jason D Goldman. Clin Infect Dis. 2021.

. 2021 Jun 1;72(11):e844-e847.

doi: 10.1093/cid/ciaa1707.

Jason D Goldman^{1

2}

¹ Swedish Center for Research and Innovation, Swedish Medical Center, Seattle, Washington, USA.
² Division of Allergy and Infectious Disease, University of Washington, Seattle, Washington, USA.

No abstract available

Keywords: COVID-19; SARS-CoV-2; Twitter; hydroxychloroquine; pandemic.

Comment on

Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial.
Rajasingham R, Bangdiwala AS, Nicol MR, Skipper CP, Pastick KA, Axelrod ML, Pullen MF, Nascene AA, Williams DA, Engen NW, Okafor EC, Rini BI, Mayer IA, McDonald EG, Lee TC, Li P, MacKenzie LJ, Balko JM, Dunlop SJ, Hullsiek KH, Boulware DR, Lofgren SM; COVID PREP team. Rajasingham R, et al. Clin Infect Dis. 2021 Jun 1;72(11):e835-e843. doi: 10.1093/cid/ciaa1571. Clin Infect Dis. 2021. PMID: 33068425 Free PMC article. Clinical Trial.